Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navicixizumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- OncXerna Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Navicixizumab + paclitaxel is a combination therapy under investigation for the treatment of platinum-resistant ovarian cancer, including fallopian tube and primary peritoneal cancers. Navicixizumab is a bispecific monoclonal antibody that targets both delta-like ligand 4 (DLL4), a Notch pathway ligand, and vascular endothelial growth factor (VEGF). By simultaneously inhibiting DLL4/Notch signaling and VEGF-mediated angiogenesis, navicixizumab disrupts tumor blood vessel formation and tumor cell proliferation. Paclitaxel is a well-established chemotherapeutic agent that interferes with microtubule function to inhibit cancer cell division. The combination has demonstrated promising clinical activity in patients who are bevacizumab-treated or naïve, with manageable toxicity profiles in phase Ib studies[1][2][4][6]. Navicixizumab was originally developed by OncoMed Pharmaceuticals; current development is sponsored by OncXerna Therapeutics[5][7].
- Brand names
- None
- Other names
- None
02
Targets
Beyond the preview
Go deeper on navicixizumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navicixizumab + paclitaxel.